[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Alignment Healthcare insider sale notice: The filing reports that 24,800 shares of Alignment Healthcare common stock are proposed for sale via Morgan Stanley Smith Barney, with an aggregate market value of $391,840, and an approximate sale date of 08/22/2025 on NASDAQ. The shares were acquired 03/06/2021 as pre-IPO shares issued in exchange for partnership units. The filer reports two prior 10b5-1 sales by Hyong J Kim on 08/11/2025 and 08/13/2025, each showing 18,600 shares sold generating gross proceeds of $270,425.40 and $279,608.22 respectively. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Detailed disclosure of planned sale amount (24,800 shares), broker (Morgan Stanley Smith Barney), and aggregate value ($391,840)
• Source of shares disclosed: acquired 03/06/2021 as pre-IPO issuance in exchange for partnership units
• Prior 10b5-1 sales disclosed (08/11/2025 and 08/13/2025), indicating use of a documented trading plan

Negative

• Insider selling activity: multiple recent sales (two prior 18,600-share transactions plus the proposed 24,800-share sale) reduce insider ownership
• Limited financial context: filing contains no explanation of purpose for sale or impact on insider ownership percentage

Insights

Securities Analyst

TL;DR: Insider plans to sell a modest parcel of shares; prior 10b5-1 transactions occurred in August 2025.

The notice documents a proposed sale of 24,800 common shares valued at $391,840, sourced from pre-IPO partnership-unit issuance on 03/06/2021. Sales will be executed through Morgan Stanley Smith Barney and are scheduled for 08/22/2025. The filing also discloses two recent 10b5-1 sales by Hyong J Kim on 08/11/2025 and 08/13/2025 of 18,600 shares each. For investors, this is a routine insider liquidity event; the amounts are small relative to the issuer's reported outstanding shares of 198,031,417, so market impact is likely limited.

Corporate Governance Expert

TL;DR: Filing shows compliance with Rule 144 and disclosure of 10b5-1 sales, indicating adherence to trading-plan transparency.

The document specifies that the securities were acquired pre-IPO and that the seller affirms no undisclosed material adverse information. The inclusion of 10b5-1 sale details and broker information suggests adherence to established insider-trading protocols. From a governance perspective, the filing provides required transparency about the timing, source, and mechanism of insider sales but does not contain additional governance changes or material corporate events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	24800	391840.00	198031417	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/06/2021	Shares Issued Pre-IPO in exchange for Partnership Units	Issuer			24800	03/06/2021	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for HYONG J KIM 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	08/13/2025	18600	279608.22
10b5-1 Sales for HYONG J KIM 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	08/11/2025	18600	270425.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares is the ALHC filing proposing to sell?

The notice proposes sale of 24,800 common shares of Alignment Healthcare (ALHC) with aggregate market value $391,840.

When is the proposed sale scheduled for ALHC?

The approximate date of sale listed is 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney.

How and when were the securities being sold originally acquired?

The securities were acquired on 03/06/2021 as pre-IPO shares issued in exchange for partnership units.

Has the filer sold ALHC shares recently?

Yes. The filing discloses two 10b5-1 sales by Hyong J Kim: 08/11/2025 (18,600 shares, $270,425.40) and 08/13/2025 (18,600 shares, $279,608.22).

Who is the broker handling the proposed ALHC sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services (1 New York Plaza, 8th Floor, New York, NY).